Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its intellectual property expertise to sustain sales.